| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_04c0e2a5d994f559e9dc5c6eeb1fd5b8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001104
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001131
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate |
2021-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f43810dfc10d0e5a3006f95728bf8ee
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d07816bc7de6b355689a891199ae0da0 |
| publicationDate |
2021-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2021273638-A1 |
| titleOfInvention |
Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors |
| abstract |
A method of treating patients suffering from cancers driven by deregulated Human Epidermal nGrowth Factor Receptor (HERI/Human EGFR) comprising administering to a patient in need of n5 such treatment a flexible and active regimen for combining a tyrosine kinase inhibitor (TKI) and nanti-EGF antibodies for inhibition of the pathway activated by EGF-EGFR binding (mAb). The nanti-EGF antibodies can be produced by active immunization or provided passively by the nadministration of antibodies that are anti-EGF. The method comprises TKI administered naccording to a continuous regimen based on an average daily dose in the range of 10 to 150 mg n.0 and the mAb is co-administered either actively or passively according to a dosing regimen nachieving a therapeutic effective amount repeated thrice, twice or once a week, once in two nweeks, once in three weeks or at least once monthly. |
| priorityDate |
2015-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |